Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 8, 2012, Pages 1069-1074

  Cavanaugh, Joseph Sean ^a   Kazennyy, B Y ^b   Nguyen, M L ^c   Kiryanova, E V ^b   Vitek, E ^a   Khorosheva, T M ^b   Nemtsova, E ^b   Cegielski, J P ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Orel Oblast Central Tuberculosis Dispensary ^*  (Russian Federation)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol; Default; Recurrence

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; THIOAMIDE;

ADULT; ALCOHOLISM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COHORT ANALYSIS; DRUG DEPENDENCE; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RUSSIAN FEDERATION; SHORT COURSE THERAPY; SPUTUM SMEAR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALCOHOLISM; ANTITUBERCULAR AGENTS; CHI-SQUARE DISTRIBUTION; DIRECTLY OBSERVED THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RUSSIA; SPUTUM; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84863580392     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0696     Document Type: Article

References (29)

1. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
2. Johnston J C, Shahidi N C, Sadatsafavi M, Fitzgerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4: e6914.
3. Chan E D, Laurel V, Strand M J, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109. (Pubitemid 38624789)
4. Nathanson E, Lambregts-van Weezenbeek C, Rich M L, et al. Multidrug-resistant tuberculosis management in resourcel imited settings. Emerg Infect Dis 2006; 12: 1389-1397. (Pubitemid 44455215)
5. Lee J, Lim H-J, Cho Y-J, et al. Recurrence after successful treatment among patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2011; 15: 1331-1333.
6. He G X, Xie Y G, Wang L X, et al. Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment. PLoS One 2010; 5: e10799.
7. Migliori G B, Espinal M, Danilova I D, Punga V V, Grzemska M, Raviglione M C. Frequency of recurrence among MDR-TB cases 'successfully' treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis 2002; 6: 858-864. (Pubitemid 35190698)
8. Becerra M C, Appleton S C, Franke M F, et al. Recurrence after treatment for pulmonary multidrug-resistant tuberculosis. Clin Infect Dis 2010; 51: 709-711.
9. Keshavjee S, Gelmanova I Y, Farmer P E, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372: 1403-1409.
10. Goldman R C, Plumley K V, Laughon B E. The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control. Infect Disord Drug Targets 2007; 7: 73-91. (Pubitemid 47099121)
11. Caminero J A. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis 2008; 12: 869-877.
12. Chan E D, Iseman M D. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis 2008; 21: 587-595.
13. Migliori G B, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626. (Pubitemid 351194820)
14. Shin S S, Keshavjee S, Gelmanova I Y, et al. Development of extensively drug-resistant tuberculosis during multidrugresistant tuberculosis treatment. Am J Respir Crit Care Med 2010; 182: 426-432.
15. Toungoussova O S, Bjune G, Caugant D A. Epidemic of tuberculosis in the former Soviet Union: social and biological reasons. Tuberculosis (Edinb) 2006; 86: 1-10. (Pubitemid 41797653)
16. World Health Organization/International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world. Report no. 2. Prevalence and trends. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Geneva, Switzerland: WHO, 2000: p 253.
17. Cox H S, Kalon S, Allamuratova S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One 2007; 2: e1126.
18. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006; 10: 402-408.
19. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
20. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326. (Pubitemid 40139109)
21. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384. (Pubitemid 39611587)
22. Gelmanova I Y, Keshavjee S, Golubchikova V T, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 2007; 85: 703-711. (Pubitemid 47416722)
23. Belilovsky E M, Borisov S E, Cook E F, Shaykevich S, Jakubowiak W M, Kourbatova E V. Treatment interruptions among patients with tuberculosis in Russian TB hospitals. Int J Infect Dis 2010; 14: e698-703.
24. Fleming M F, Krupitsky E, Tsoy M, et al. Alcohol and drug use disorders, HIV status and drug resistance in a sample of Russian TB patients. Int J Tuberc Lung Dis 2006; 10: 565-570. (Pubitemid 43667647)
25. Zaridze D, Brennan P, Boreham J, et al. Alcohol and causes pecific mortality in Russia: a retrospective case-control study of 48,557 adult deaths. Lancet 2009; 373: 2201-2214.
26. Dewan P K, Arguin P M, Kiryanova H, et al. Risk factors for death during tuberculosis treatment in Orel, Russia. Int J Tuberc Lung Dis 2004; 8: 598-602. (Pubitemid 38625066)
27. Jakubowiak W M, Bogorodskaya E M, Borisov E S, Danilova I D, Kourbatova E K. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis 2007; 11: 46-53. (Pubitemid 46101845)
28. Greenfield S F, Shields A, Connery H S, et al. Integrated management of physician-delivered alcohol care for tuberculosis patients: design and implementation. Alcohol Clin Exp Res 2010; 34: 317-330.
29. Raviglione M C, Smith I M. XDR tuberculosis - implications for global public health. N Engl J Med 2007; 356: 656-659.